South Africa Lands R1.5 Billion Deal to Build Africa’s First Major Vaccine Manufacturer
By TUW
South Africa is preparing to establish Africa’s first fully integrated vaccine production facility following a major R1.5 billion investment agreement involving Biovac and European financial partners. The project is expected to strengthen the continent’s healthcare independence by allowing vaccines to be developed, produced and distributed locally instead of relying heavily on imports.
Construction of the facility is expected to be completed by 2028, with the first phase focusing on the production of oral cholera vaccines. Plans are already in place to later expand manufacturing to include vaccines for diseases such as polio, pneumonia and meningitis.
Health experts say the project could play a major role in improving vaccine access across Africa, especially during outbreaks and global shortages. The plant is also expected to create hundreds of skilled jobs while supporting scientific research, pharmaceutical innovation and local industrial growth.
The investment further reflects South Africa’s growing cooperation with the European Union in areas such as healthcare, technology and economic development. Analysts believe the partnership could help position the country as one of Africa’s leading pharmaceutical and medical manufacturing hubs in the coming years.
At the same time, South African authorities have highlighted the country’s quick response to a recent hantavirus-related health concern. Officials say rapid tracing measures and strong disease monitoring systems demonstrate the country’s preparedness in dealing with emerging public health threats.
